Shots:

• The companies collaborate for fast-track development of DNP-019 against COVID-19
• The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development- process development- to non-clinical and clinical material manufacturing
• Samsung has introduced its proprietary cell-line technology- S-CHOice- demonstrating improved titers up to two-fold and maintaining over 90% cell viability

 ­ Ref: PRNewswire | Image: Twitter